Zacks: Analysts Expect MEDNAX Inc (MD) Will Announce Quarterly Sales of $886.36 Million

Wall Street brokerages forecast that MEDNAX Inc (NYSE:MD) will announce sales of $886.36 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for MEDNAX’s earnings, with estimates ranging from $876.50 million to $894.51 million. MEDNAX posted sales of $830.77 million in the same quarter last year, which suggests a positive year over year growth rate of 6.7%. The business is expected to report its next earnings results on Tuesday, February 6th.

On average, analysts expect that MEDNAX will report full-year sales of $886.36 million for the current financial year, with estimates ranging from $3.42 billion to $3.44 billion. For the next financial year, analysts expect that the firm will post sales of $3.66 billion per share, with estimates ranging from $3.59 billion to $3.75 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for MEDNAX.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. MEDNAX had a return on equity of 10.80% and a net margin of 7.76%. The company had revenue of $868.95 million for the quarter, compared to analyst estimates of $864.78 million. During the same quarter last year, the firm earned $1.09 EPS. MEDNAX’s revenue for the quarter was up 4.9% compared to the same quarter last year.

MD has been the topic of several recent analyst reports. Jefferies Group reaffirmed a “hold” rating and issued a $44.00 price target on shares of MEDNAX in a research note on Friday, November 3rd. Citigroup decreased their price target on MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. KeyCorp set a $51.00 price target on MEDNAX and gave the company a “buy” rating in a research note on Wednesday, November 1st. BMO Capital Markets initiated coverage on MEDNAX in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 price target on the stock. Finally, Robert W. Baird boosted their price target on MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company. MEDNAX has a consensus rating of “Hold” and a consensus price target of $53.82.

In related news, insider John C. Pepia sold 3,000 shares of MEDNAX stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of MEDNAX stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in MD. BlackRock Inc. grew its stake in MEDNAX by 0.3% in the second quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock valued at $498,505,000 after acquiring an additional 28,155 shares during the period. Vanguard Group Inc. grew its stake in MEDNAX by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock valued at $455,862,000 after acquiring an additional 38,645 shares during the period. Thompson Siegel & Walmsley LLC grew its stake in MEDNAX by 19.7% in the third quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock valued at $112,065,000 after acquiring an additional 428,184 shares during the period. Nordea Investment Management AB grew its stake in MEDNAX by 4.8% in the third quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock valued at $100,198,000 after acquiring an additional 106,883 shares during the period. Finally, Earnest Partners LLC grew its stake in MEDNAX by 0.7% in the third quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock valued at $64,437,000 after acquiring an additional 11,037 shares during the period. 98.43% of the stock is owned by institutional investors and hedge funds.

Shares of MEDNAX (NYSE MD) opened at $53.52 on Friday. MEDNAX has a fifty-two week low of $40.56 and a fifty-two week high of $72.13. The firm has a market capitalization of $5,010.00, a P/E ratio of 18.98, a PEG ratio of 1.56 and a beta of 0.39. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/21/zacks-analysts-expect-mednax-inc-md-will-announce-quarterly-sales-of-886-36-million.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply